With a clear focus on complex products, Lupin sets out its launch plans for the year ahead, while battling ongoing litigation over some of its generics.
Lupin has its eyes on the prize – strengthen its position and co-exclusivity of generic mirabegron. During a recent investors’ call covering Lupin’s financial first quarter, CEO Vinita Gupta said that the firm is evaluating when to launch its 50mg generic rival to Astellas’ Myrbetriq, but it all depends on the ongoing litigation outcome relating to the US patent 10,842,780.
It has not been the easiest ride for the firm and its generic drug. In April, Lupin and fellow Indian...
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
This article compiles all of the data from Generics Bulletin’s 2024 ranking of the Top 50 firms across the generics and biosimilars industry, including additional details of how the various financial figures stack up.
